AAMU
UROV

Amundi Asset Management US’s Urovant Sciences Ltd. UROV Stock Holding History

Amundi Asset Management US’s Portfolio UROV Stock Details UROV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-16,186
Closed -$128K – 1740
2019
Q2 		$128K Buy
+16,186
New +$133K ﹤0.01% 1546

Other funds holding UROV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Amundi Asset Management US's UROV Position: Q3 2019 in Review

Amundi Asset Management US sold out of Urovant Sciences Ltd. (UROV) in Q3 2019, closing a stake of 16,186 shares — an estimated $128K sold.

Amundi Asset Management US first reported a position in UROV in Q2 2019 and held it in 1 quarter. The position peaked at $128K in Q2 2019. 27 funds tracked by Wall St. Rank hold UROV as of Q3 2019.

  • Amundi Asset Management US reported no remaining Urovant Sciences Ltd. position as of Q3 2019 after selling out during the quarter.
  • Amundi Asset Management US sold 16,186 Urovant Sciences Ltd. shares in Q3 2019, an estimated $128K.
  • Amundi Asset Management US first reported a position in Urovant Sciences Ltd. in Q2 2019 and held it in 1 quarter.
  • Amundi Asset Management US's Urovant Sciences Ltd. position peaked at $128K in Q2 2019.
  • 27 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q3 2019.

Based on Amundi Asset Management US's 13F filing for Q3 2019, filed 14 Nov 2019.